Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median...
Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median...
Elicio Therapeutics股票下跌，因公司宣佈ELI-002 7P第1a階段研究初步無病生存分析顯示，接受4.9mg AMP-peptide劑量的患者尚未達到中位數...
Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median DFS Endpoint as of the May 24 Cutoff Date.
Elicio Therapeutics股票下跌，公司宣佈ELI-002 7P一期臨床試驗的初步無病生存分析，顯示用量爲4.9毫克AMP肽的患者在截至5月24日的中位無病生存終點尚未到達。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。